Document is current
Any future updates will be listed below
-
Authors
van Heusden, Fran C.
van Nifterick, Anne M.
Souza, Bryan C.
França, Arthur S. C.
Nauta, Ilse M.
Stam, Cornelis J.
Scheltens, Philip
Smit, August B.
Gouw, Alida A.
van Kesteren, Ronald E.
-
Funding
Funding for this research was provided by:
Netherlands Organization for Health Research and Development (91218018, 91218018, 733050812, 91218018)
- License Information
-
More Information
Article History
Received: 10 March 2023
Accepted: 11 August 2023
First Online: 22 August 2023
Declarations
:
: All animal experiments were approved by the Central Committee for Animal Experiments and the Animal Welfare Body of the Vrije Universiteit Amsterdam in full compliance with the directive 2010/63/EU. All participants provided written informed consent for the use of their data for research purposes.
: Not applicable.
: Dr Scheltens is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB. He is past chair of the EU steering committee of the phase 2b program of Vivoryon and the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk. Dr Van Kesteren serves on the Scientific Advisory Board of Alzheimer Nederland. All other authors report no competing interests.
